Sector Gamma AS increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 475,056 shares of the biopharmaceutical company’s stock after purchasing an additional 30,000 shares during the period. Gilead Sciences accounts for about 5.1% of Sector Gamma AS’s holdings, making the stock its 5th biggest holding. Sector Gamma AS’s holdings in Gilead Sciences were worth $30,109,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently added to or reduced their stakes in GILD. Advisors Preferred LLC purchased a new position in shares of Gilead Sciences in the second quarter valued at approximately $26,000. First Financial Corp IN boosted its stake in shares of Gilead Sciences by 286.4% in the third quarter. First Financial Corp IN now owns 541 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 401 shares during the period. Legacy Advisors LLC purchased a new position in shares of Gilead Sciences in the second quarter valued at approximately $37,000. Venturi Wealth Management LLC purchased a new position in shares of Gilead Sciences in the third quarter valued at approximately $40,000. Finally, Evolution Wealth Advisors LLC purchased a new position in shares of Gilead Sciences in the second quarter valued at approximately $46,000. Hedge funds and other institutional investors own 79.91% of the company’s stock.
GILD has been the subject of several recent research reports. JPMorgan Chase & Co. reissued a “buy” rating and issued a $85.00 price objective on shares of Gilead Sciences in a research note on Wednesday, July 31st. Jefferies Financial Group set a $95.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Monday, July 15th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Monday, July 15th. Royal Bank of Canada raised shares of Gilead Sciences from an “outperform” rating to a “top pick” rating and set a $91.00 price objective for the company in a research note on Monday, July 29th. Finally, Wells Fargo & Co set a $81.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Friday, October 25th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, fourteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $79.27.
Gilead Sciences stock traded up $1.42 during trading on Friday, reaching $65.38. The stock had a trading volume of 4,953,000 shares, compared to its average volume of 6,639,518. The company has a quick ratio of 2.96, a current ratio of 3.06 and a debt-to-equity ratio of 1.13. The stock has a market cap of $82.81 billion, a PE ratio of 10.63, a P/E/G ratio of 3.47 and a beta of 1.09. The business has a 50 day moving average price of $64.15 and a 200 day moving average price of $65.25. Gilead Sciences, Inc. has a 52-week low of $60.32 and a 52-week high of $72.90.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 24th. The biopharmaceutical company reported $1.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.74 by $0.01. The company had revenue of $5.60 billion for the quarter, compared to analysts’ expectations of $5.61 billion. Gilead Sciences had a net margin of 12.04% and a return on equity of 37.50%. Gilead Sciences’s revenue was up .1% compared to the same quarter last year. During the same period in the previous year, the company posted $1.84 EPS. On average, equities analysts predict that Gilead Sciences, Inc. will post 6.66 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, December 12th. This represents a $2.52 annualized dividend and a dividend yield of 3.85%. Gilead Sciences’s payout ratio is currently 40.98%.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Featured Article: Profit margin is different from the revenue
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.